Coding Tip: New Technology ICD-10-PCS Section “X” Drugs for FY2019
RHIA, CDIP, CCS, CCS‑P, CIRCC
Executive Director Of Education
AHIMA‑Approved ICD‑10‑CM/PCS Trainer and Ambassador
Section “X” is a separate place within ICD-10-PCS for certain new technology procedures (such as new technology drugs). Section “X” does not introduce any new coding concepts or unusual guidelines for correct coding and maintains continuity with the other sections in ICD-10-PCS. The same root operation and body part values are used in section “X” as in other sections. The seventh character in section “X” is used to indicate the new technology group. This is a number or letter that changes each year that new technology codes are added. It is only used to indicate the year the code was created and all codes for that update year will have the same qualifier. The new technology drugs for FY2019 will have the qualifier/seventh character of “4” since this is the third year of ICD-10-PCS.
Section “X” codes are standalone codes. No additional codes from other sections in ICD-10-PCS are necessary for reporting as the specific procedure is described in the code title from section “X”.
New Technology section codes are easily found by looking in the ICD-10-PCS Index or the Tables. The name of the new technology device, substance or technology for a section “X” code is included as the main term. They are also listed under the main term “New Technology”.
New technology items have a new technology payment that is made in addition to the DRG payment for hospital inpatients. Missing new technology codes is a frequent error made by coders. Coders must familiarize themselves with the new technologies of each year.
There are several substance values continuing in the code table XW0 (anatomical regions, introduction) for FY2019.
- A—Bezlotoxumab Monoclonal Antibody/ZINPLAVA™ (XW033A3, XW043A3) The maximum a hospital can received for this is $1,900 as new technology payment.
- B—Cytarabine and Daunorubicin Liposome Antineoplastic/VYXEOS™ (XW033B3, XW043B3) The maximum the hospital can receive for this is $36,425 as a new technology payment.
- C—Engineered Autologous Chimeric Antigen Receptor T-Cell Immunotherapy/KTE-C19/axicabtagene ciloleucel/CAR-T therapy (XW033C3, XW043C3) The maximum payment a hospital can receive for this is $186,500 as a new technology payment
- F—Ustekinumab/STELARA™ (XW033F3, XW043F3) The maximum the hospital can receive for this is $2,400 as a new technology payment.
- 9—Defibrotide sodium/DIFETELIO® (XW03392, XW04392) The maximum the hospital can receive for this is $80,500 as a new technology payment.
There were five new substance values added to the code table XW0 (anatomical regions, introduction) for FY 2019.
- C—Axicabtagene Ciloleucel/YESCARTA™ and Tisagenlecleucel/KYMRIAH (XW033C3, XW043C3) These are two new CAR T therapies for FY2019. The maximum payment a hospital can receive for this is $186,500 as a new technology payment
- G—Plazonmicin/ZEMDRI™ (XW033G4, XZW043G4) The maximum a hospital can receive for this is $2,722.50 as a new technology payment.
- H—GIAPREZA™ (XW033H4, XW043H4) The maximum payment a hospital can receive for this is $1,500 as a new technology payment.
- D—Meropenem-vaborbactam/VABOMERE™ (XW033F3, XW043F3 – there is no unique code for VABOMERE) For FY 2019, cases “eligible for the FY 2019 new technology add-on payments will be identified by the NDC of 65293-009-01 (VABOMERE™ Meropenem-Vaborbactam Vial). Providers must code the NDC in data element LIN03 of the 837i Health Care Claim Institutional form in order to receive the new technology add-on payment for procedures involving the use of VABOMERE™” The maximum payment a hospital can receive for this is $5,544 as a new technology payment.
- 7—Andexanet alfa/AndexXa™ (XW03372, XW04372) AndexXa is a newer form of Andexanet Alfa. The maximum payment a hospital can receive for this is $14,062.50 as a new technology payment.
New Technology Drugs for 2018 – 2019
AndexXa™ (Andexanet alfa) is an antidote used to treat patients who are receiving treatment with an oral Factor Xa inhibitor who suffer a major bleeding episode and require urgent reversal of direct and indirect Factor Xa anticoagulation. Patients at high risk for thrombosis, including those who have been diagnosed with atrial fibrillation (AF) and venous thrombosis (VTE), typically receive treatment using long-term oral anticoagulation agents.
Axicabtagene Ciloleucel (YESCARTA™) and Tisagenlecleucel (KYMRIAH™). (Fights non-Hodgkin’s Lymphoma and Acute Lymphoblastic Leukemia) For these CAR T-Cell therapies. Both are given IV.
Bezlotoxumab (ZINPLAVA™) —this drug is used in patients with Clostridium difficile (C. diff) diarrhea who are already on antibiotics and have a high risk of recurrence. Up to 25% of patients with C. diff will have a recurrence of the bacteria. Use of this drug helps to reduce recurrence of the bacteria. This drug is a human monoclonal antibody targeting the C. diff toxin B and does not affect the GI microbiota like the antibacterial drugs do. This drug is administered by IV.
Cytarabine/ and Daunorubicin (VYXEOS™)—this drug is used in patients with newly diagnosed therapy related acute myeloid leukemia (t-AML) or AML. VYXEOS delivers and maintains fixed ratios of Cytarabine and Daunorubicin and provides prolonged exposure in the bone marrow. Both Cytarabine and Daunorubicin are existing chemotherapy drugs and are commonly used but VYXEOS is a specific formula of the two drugs. This is administered by IV.
Defibrotide sodium (DEFITELIO®) is treatment for patients diagnosed with hepatic veno-occlusive disease (VOD) with evidence of multiorgan dysfunction. Also known as sinusoidal obstruction syndrome. This is a life threatening complication of hematopoietic stem cell transplantation (HSCT). Treatment is 25 mg/day for 21 + days.
Engineered Autologous Chimeric Antigen Receptor T-Cell Immunotherapy/KTE-C19/axicabtagene ciloleucel/CAR-T therapy—this engineered autologous immunotherapy is used to treat patients with relapsed or refractory B-cell non-Hodgkin lymphoma who are eligible for an autologous stem cell transplant. This represents a new paradigm in antineoplastic therapy. In this, the patient’s own T-cells are harvested and engineered to target specific antigens. After this is infused back into the patient, the genetically engineered T-cells find the target cells and kill them.
GIAPREZA™ a synthetic human angiotensin II, is administered through IV infusion to raise blood pressure in adult patients who have been diagnosed with septic or other distributive shock.
Neropenem-vaborbactam (VABOMERE™) Given IV for adults with complicated UTIs and acute pyelonephritis (chills, rigors, temp higher than 38C, WBC over 10,000, etc.)
Plazonmicin (ZEMDRI™) Next generation aminoglycoside antibiotic to treat multi-drug resistant gram-negative bacteria, usually complicated UTI (cUTI) or pyelonephritis. It is given IV.
Ustekinumab (STELARA™) is an IV infusion treatment for Crohn’s disease. Only for use in patients over 18 with moderately to severely active Crohn’s disease.
AHA ICD-10-CM/PCS Coding Clinic, Fourth Quarter 2018 Page 56
The information contained in this post is valid at the time of posting. Viewers are encouraged to research subsequent official guidance in the areas associated with the topic as they can change rapidly.
In 2003, the Centers for Medicare and Medicaid Services (CMS) implemented Risk Adjustment Factors (RAF) and Hierarchical Condition Category (HCC) coding to identify individuals with serious and/or chronic illnesses and assign them a risk factor score that is based on a combination of demographic information and reported diagnoses.
The ICD-10-CM/PCS code changes – effective October 1, 2018 to September 31, 2019 – could be the culprit. Comparatively speaking, there are far less changes this year than in years past. The release includes: 279 new codes, 51 deleted codes,143 revised codes. But don’t let the smaller amount of changes fool you…
With the publication of the new ICD-10-CM Official Guidelines for Coding and Reporting for FY 2019, we finally have an answer regarding reporting of BMI in pregnancy. The new guideline does state “do not assign BMI codes during pregnancy.”
Conflicting documentation occurs when health care providers call the same condition different things. When none of the documented conditions are clearly ruled out by the physician, coders may find it necessary to query for the most appropriate diagnosis.
In reviewing hundreds of contracts, the OIG found that insurers overturned 75% of their own denials upon appeal—approximately 216,000 denials each year. However, while the odds of winning an appeal are seemingly good, many providers simply don’t have the time or the internal staff and infrastructure needed to engage in the process.
When coding a record with documented bullying, this is coded as child or adult psychological abuse (initial/subsequent encounter or sequela) either as confirmed or suspected. The encounter and whether this is confirmed or suspected is needed in order to assign the appropriate diagnosis code.
It’s Halloween season! It’s time to overindulge on candy, fight over the best costume, become irrationally scared of things like the number 13, and have nightmares of your 6th birthday with that terrifying clown. As for us, we’re getting in the spirit with 13 spooky ICD- 10 codes! Beware – it’s scary out there.
Coding Tip: New ICD-10-CM General Coding Guideline — Coding for Healthcare Encounters in Hurricane Aftermath
With the Hurricane season in full swing, this new guideline will be helpful in reporting the external cause codes when an injury occurs as a result of the hurricane, and also help in determining sequencing of the reported codes.
The refined Stroke 30-day mortality measure (MORT-30-STK) is a statistic defined as death occurring within 30 days of a diagnosed stroke. The Centers for Medicare & Medicaid Services (CMS) publicly reports a 30-day hospital-level stroke mortality measure on Hospital Compare as part of the Inpatient Quality Reporting (IQR) program.
“Lobar” pneumonia references a form of pneumonia that affects a specific lobe or lobes of the lung. This is a bacterial pneumonia and is most commonly community acquired. Antibiotics are almost always necessary to clear this type of pneumonia.
We have seen a lot of recommendations of late where the coders are coding hydronephrosis, UTI and ureteral stone separately or not with the correct code to include all conditions.
Coders have struggled for some time with the dilemma of when to assign the combination code of carotid stenosis, with cerebral infarction (i.e.I63.231) and when to assign separate codes for the specific cerebral infarction and carotid stenosis. (i.e. I66.01 and I65.21).
Queries in a Yes/No format are limited to use in the four specific circumstances. This format may not be used when only clinical indicators of a condition are present, but the diagnosis has not been documented in the health record.
Queries written in a multiple-choice format include a short list of options for physician response. These options must be relevant and supported by the clinical indicators included in the query.
Since the implementation of ICD-10-PCS in 2015, yearly changes have been made regarding the definition of, and guidelines associated with, the root operation Control. This has caused coding professionals much confusion in determining whether to assign a procedure to root operation Control, to assign another root operation, or to not assign a procedure code at all.
The policies in the IPPS/LTCH PPS final rule further advance the agency’s priority of creating a patient-centered healthcare system by achieving greater price transparency, interoperability, and significant burden reduction so that hospitals can operate with better…
In this current, ever-changing healthcare climate, health systems face many challenges. Facilities large and small must be dedicated to improving documentation and reducing complications, HACs, infection rates, and readmissions as they endeavor towards value-based care. Coding inaccuracies can really undermine…
It’s imperative, in today’s challenging healthcare environment, that organizations demand complete and accurate coding practices from their vendors if they want: Appropriate and timely reimbursement; Representative quality measures; Improved CMI; Reduction in payor denials and; Mitigation of compliance risks.
In addition to positive clinical indicators documented at the time of admission, any of these that occur within the few days after admission should also be included. This will support the fact that sepsis could have developed after admission. It is important that a POA query give equal attention to what supports POA yes, as well as POA no to avoid the appearance of a leading query.
This major proposed rule addresses changes to the Medicare physician fee schedule (PFS) and other Medicare Part B payment policies to ensure that our payment systems are updated to reflect changes in medical practice and the relative value of services, as well as changes in the statute.
For example, open the ICD-11 online link and click on “Browse the release version.” Then choose “Coding Tool” tab at the top. We chose “sepsis.” Sepsis without shock is coded to 1G40. Sepsis with septic shock is coded 1G41. A bit different than ICD-10!
Did you know that by coding hypertension with associated CKD correctly along with any surgical dialysis access creation on patients admitted with hypertension, will keep the case out of the AHRQ PQI #07: Hypertension Admission Rate quality measure?
From a coding perspective, the IABP is not classified as a device such as the VAD’s. The IABP is not coded as a device within ICD-10-PCS and is coded with the root operation of “Assistance.” The ICD-10-PCS code for insertion of an IABP for continuous pumping would be 5A02210, Extracorporeal or Systemic Assistance, Physiologic Systems, Assistance, Cardiac, Continuous, Output, Balloon Pump.
The key to a quality physician query is the question. The question provides direction for the choice of clinical indicators and options for response. So why do so many coders have trouble writing the question? My theory is that coders overthink the question rather than keeping it simple and to the point. The best way to get a physician to answer a query is with a question that makes sense and eliminates guessing as to what is being asked.
Locating ventilator times were difficult in the paper medical record, but has not become any easier with the implementation on the electronic health record (EHR.) Coders should be encouraged to review the record for exact ventilator times. As mentioned above, this could come down to minutes when selecting the correct ICD-10-PCS code.
Hamilton. If you haven’t seen it, you’ve heard of it. The Broadway mega-hit has been the toughest ticket on Broadway since its debut in 2015. For the uninitiated, Hamilton explores the life and triumphs of the previously obscure “ten-dollar founding father,” Alexander Hamilton, through rap, hip-hop, and musical theatre.
Procedure code assignment for excisional debridement has always been a focus area in coding audits. The biggest concern is whether or not the debridement is truly excisional in nature, and if the documentation truly supports an excisional debridement. HIA has written a previous Coding Tip on determining nonexcisional vs excisional debridement.
Beth Martilik, MA, RHIA, CDIP, CCS Assistant Director of Education AHIMA Approved ICD‑10 Trainer and Ambassador The ultimate goal of a physician query is to obtain clarity to physician documentation in the patient’s health record. In order to accomplish this goal,...